Showing results (331-340 of 369) with videos related to

Sort By:
Pageof 37
NEJM Evidence|February 6, 2024
Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER TrialsToru Kondo, Samvel B Gasparyan, Pardeep S Jhund, et al.
The Journal of Clinical Endocrinology and Metabolism|July 21, 2026
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?Silvio E Inzucchi, Rohana Abdul Ghani, John Deanfield, et al.
Nature Medicine|December 15, 2022
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trialOrly Vardeny, James C Fang, Akshay S Desai, et al.
Circulation|March 29, 2025
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized TrialNikolaus Marx, John E Deanfield, Johannes F E Mann, et al.
Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.
Circulation. Heart Failure|October 18, 2024
Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection FractionSenthil Selvaraj, Shachi Patel, Andrew J Sauer, et al.
JACC. Heart Failure|January 2, 2023
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HFCarly Adamson, Paul Welsh, Kieran F Docherty, et al.
The New England Journal of Medicine|August 28, 2018
Cardiovascular Safety of Lorcaserin in Overweight or Obese PatientsErin A Bohula, Stephen D Wiviott, Darren K McGuire, et al.
European Heart Journal|May 23, 2023
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVERJawad H Butt, Toru Kondo, Mingming Yang, et al.
JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Pageof 37